(MRK) Merck KGaA - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: XETRA (Germany) | Market Cap: 47.739m EUR | Total Return: 1.3% in 12m
Pharmaceuticals, Chemicals, Electronics, Research
Total Rating 44
Safety 87
Buy Signal -0.01
Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.4
Industry Rotation: -2.4
Market Cap:
55.7B
Avg Turnover: 33.0M EUR
Avg Turnover: 33.0M EUR
ATR:
3.00%
Peers RS (IBD): 23.8
Peers RS (IBD): 23.8
Risk 5d forecast
Volatility28.1%
Rel. Tail Risk-8.40%
Reward TTM
Sharpe Ratio0.04
Alpha-20.79
Character TTM
Beta0.564
Beta Downside-0.015
Drawdowns 3y
Max DD40.46%
CAGR/Max DD-0.25
EPS (Earnings per Share)
EPS CAGR: -6.41%
EPS Trend: -65.9%
EPS Trend: -65.9%
Last SUE: -0.29
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 0.26%
Rev. Trend: -40.3%
Rev. Trend: -40.3%
Last SUE: -1.27
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: MRK Merck KGaA
Merck KGaA is a German science and technology company with global operations.
Its business model is diversified across three segments. The Life Science segment provides tools, chemicals, and equipment to academic, biotech, pharmaceutical, and industrial sectors. This includes reagents, consumables, and services for research and manufacturing. The pharmaceutical industry heavily relies on such tools for drug discovery and development.
The Healthcare segment focuses on the discovery, development, manufacturing, and marketing of prescription drugs and biopharmaceuticals. This segment addresses therapeutic areas such as oncology, neurology, immunology, and fertility. The biopharmaceutical market is characterized by high research and development costs and long development cycles.
The Electronics segment supplies materials and equipment for the semiconductor and display industries, including thin films, specialty gases, and optical metrology equipment. This sector is critical for the production of modern electronic devices.
Merck KGaA also engages in in-licensing agreements, such as those with Jiangsu Hengrui Pharmaceuticals and Abbisko Therapeutics, for drug development and commercialization.
For more detailed financial analysis, consider exploring ValueRays comprehensive reports.
- Healthcare segment drug approvals and sales drive revenue
- Life Science tools and services demand impacts growth
- Electronics segment semiconductor material sales influence performance
- R&D pipeline success and failures affect future earnings
- Regulatory changes in pharmaceutical and chemical industries pose risks
Piotroski VR‑10 (Strict)
6.0
| Net Income: 2.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.01 > 1.0 |
| NWC/Revenue: 19.85% < 20% (prev 10.19%; Δ 9.66% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.93b > Net Income 2.61b |
| Net Debt (9.23b) to EBITDA (6.55b): 1.41 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (434.8m) vs 12m ago 0.0% < -2% |
| Gross Margin: 58.51% > 18% (prev 0.59%; Δ 5.79k% > 0.5%) |
| Asset Turnover: 40.71% > 50% (prev 41.03%; Δ -0.32% > 0%) |
| Interest Coverage Ratio: 10.53 > 6 (EBITDA TTM 6.55b / Interest Expense TTM 404.0m) |
Altman Z''
3.69
| A: 0.08 (Total Current Assets 13.23b - Total Current Liabilities 9.04b) / Total Assets 52.10b |
| B: 0.46 (Retained Earnings 24.01b / Total Assets 52.10b) |
| C: 0.08 (EBIT TTM 4.25b / Avg Total Assets 51.83b) |
| D: 1.06 (Book Value of Equity 24.78b / Total Liabilities 23.44b) |
| Altman-Z'' Score: 3.69 = AA |
Beneish M
-2.89
| DSRI: 1.17 (Receivables 4.77b/4.08b, Revenue 21.10b/21.16b) |
| GMI: 1.01 (GM 58.51% / 59.01%) |
| AQI: 1.02 (AQ_t 0.56 / AQ_t-1 0.54) |
| SGI: 1.00 (Revenue 21.10b / 21.16b) |
| TATA: -0.03 (NI 2.61b - CFO 3.93b) / TA 52.10b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of MRK shares?
As of April 13, 2026, the stock is trading at EUR 111.85 with a total of 240,768 shares traded.
Over the past week, the price has changed by +4.19%, over one month by +0.77%, over three months by -14.78% and over the past year by +1.31%.
Over the past week, the price has changed by +4.19%, over one month by +0.77%, over three months by -14.78% and over the past year by +1.31%.
Is MRK a buy, sell or hold?
Merck KGaA has no consensus analysts rating.
What are the forecasts/targets for the MRK price?
| Analysts Target Price | - | - |
Merck KGaA (MRK) - Fundamental Data Overview
as of 12 April 2026
Market Cap USD = 55.66b (47.74b EUR * 1.1659 EUR.USD)P/E Trailing = 18.3
P/E Forward = 13.5685
P/S = 2.2623
P/B = 1.6696
P/EG = 1.5591
Revenue TTM = 21.10b EUR
EBIT TTM = 4.25b EUR
EBITDA TTM = 6.55b EUR
Long Term Debt = 10.21b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.24b EUR (from shortTermDebt, last quarter)
Debt = 11.97b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.23b EUR (from netDebt column, last quarter)
Enterprise Value = 56.97b EUR (47.74b + Debt 11.97b - CCE 2.74b)
Interest Coverage Ratio = 10.53 (Ebit TTM 4.25b / Interest Expense TTM 404.0m)
EV/FCF = 27.34x (Enterprise Value 56.97b / FCF TTM 2.08b)
FCF Yield = 3.66% (FCF TTM 2.08b / Enterprise Value 56.97b)
FCF Margin = 9.88% (FCF TTM 2.08b / Revenue TTM 21.10b)
Net Margin = 12.36% (Net Income TTM 2.61b / Revenue TTM 21.10b)
Gross Margin = 58.51% ((Revenue TTM 21.10b - Cost of Revenue TTM 8.76b) / Revenue TTM)
Gross Margin QoQ = 56.41% (prev 60.42%)
Tobins Q-Ratio = 1.09 (Enterprise Value 56.97b / Total Assets 52.10b)
Interest Expense / Debt = 1.01% (Interest Expense 121.0m / Debt 11.97b)
Taxrate = 19.20% (77.0m / 401.0m)
NOPAT = 3.44b (EBIT 4.25b * (1 - 19.20%))
Current Ratio = 1.46 (Total Current Assets 13.23b / Total Current Liabilities 9.04b)
Debt / Equity = 0.42 (Debt 11.97b / totalStockholderEquity, last quarter 28.59b)
Debt / EBITDA = 1.41 (Net Debt 9.23b / EBITDA 6.55b)
Debt / FCF = 4.43 (Net Debt 9.23b / FCF TTM 2.08b)
Total Stockholder Equity = 28.90b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.03% (Net Income 2.61b / Total Assets 52.10b)
RoE = 9.02% (Net Income TTM 2.61b / Total Stockholder Equity 28.90b)
RoCE = 10.87% (EBIT 4.25b / Capital Employed (Equity 28.90b + L.T.Debt 10.21b))
RoIC = 10.83% (NOPAT 3.44b / Invested Capital 31.73b)
WACC = 6.54% (E(47.74b)/V(59.71b) * Re(7.97%) + D(11.97b)/V(59.71b) * Rd(1.01%) * (1-Tc(0.19)))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 83.50% ; FCFF base≈2.08b ; Y1≈1.97b ; Y5≈1.87b
[DCF] Fair Price = 296.6 (EV 47.56b - Net Debt 9.23b = Equity 38.34b / Shares 129.2m; r=6.54% [WACC]; 5y FCF grow -6.91% → 3.0% )
EPS Correlation: -65.94 | EPS CAGR: -6.41% | SUE: -0.29 | # QB: 0
Revenue Correlation: -40.33 | Revenue CAGR: 0.26% | SUE: -1.27 | # QB: 0
EPS next Quarter (2026-06-30): EPS=2.08 | Chg7d=-0.014 | Chg30d=+0.038 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=7.71 | Chg7d=-0.008 | Chg30d=-0.324 | Revisions Net=-6 | Growth EPS=-7.5% | Growth Revenue=-0.5%
EPS next Year (2027-12-31): EPS=8.58 | Chg7d=-0.000 | Chg30d=-0.409 | Revisions Net=-5 | Growth EPS=+11.2% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.5% (Discount Rate 8.0% - Earnings Yield 5.5%)
[Growth] Growth Spread = -2.7% (Analyst -0.2% - Implied 2.5%)